La catena delle opzioni mostra i dati chiave delle opzioni azionarie di DeepMarkit a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per DeepMarkit..

DeepMarkit (OTC:MKTDF) Azioni, Catena delle Opzioni

DeepMarkit Corp is a technology company focused on commercializing new technologies in the areas of green tech and AI technologies. Its experienced capital markets team is evaluating multiple opportunities to bring to market to create shareholder value.

DeepMarkit Corp

Biotech

News

General

ADIL

Adial Pharmaceuticals Received Milestone Payment From Adovate Following Initiation Of Phase 1 Study; Adial Eligible To Receive More Than $50M In Commercial Milestone Payments Plus Additional $11M In Development And Approval Milestone Payments Per Compound

Baird analyst Shrenik Kothari maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and raises the price target from $26 to $28.

Price Target

Analyst Ratings

Baird Maintains Neutral on Rapid7, Raises Price Target to $28

New Fortress Energy Subsidiary Executes 3-Yr Charter Agreement For Energos Freeze With Energía 2000 In Dominican Republic

SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) reported quarterly earnings of $1.16 per share. This is a 123.08 percent increase over earnings of $0.52 per share from the same period last year. The company reported $12.73 billion in sales this quarter. This is a 7.65 percent increase over sales of $11.82 billion the same period last year.

Earnings

SFTBY

SoftBank Group Q4 Earnings Per ADS $1.16 Up From $0.52 YoY, Sales $12.73B Up From $11.82B YoY

Baird analyst Ben Kallo maintains Essential Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>) with a Outperform and lowers the price target from $47 to $46.

WTRG

Baird Maintains Outperform on Essential Utilities, Lowers Price Target to $46

Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase II clinical trial evaluating ONP-002, the Company's proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion.
This approval marks a significant milestone in expanding Oragenics' clinical development efforts internationally. With this clearance, Oragenics can initiate clinical trials in Australia and could begin patient enrollment as early as the second quarter of 2025. Once the Company is prepared to commence enrollment, patient enrollment and treatment administration is expected to occur in level 1 trauma emergency departments where concussed patients are often seen following motor vehicle accidents, falls, and contact sports.

OGEN

Oragenics Receives Approval From HREC In Australia To Initiate Phase II Clinical Trial Evaluating ONP-002 For Treatment Of mTBI

An experienced IT worker recently shared his frustration on <a href="https://www.reddit.com/r/careerguidance/comments/1khuzya/im_being_laid_off_but_company_wants_me_to_train/">Reddit</a> after his employer informed him that he'd be laid off in two weeks but still expected to train his replacements. After a decade in the field, he's pushing back against the request, saying he won't be &#8216;used then tossed aside like garbage.&#8217;
<h2 class="wp-block-heading">A Tough Situation</h2>
&#8220;What you're holding is known as tribal knowledge — the kind of operational understanding that lives in the minds of experienced employees but was never properly documented by leadership. That's on them, not you,&#8221; one commenter wrote, capturing a common theme in the replies.
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
Several commenters emphasized that the company&#8217;s failure to document critical processes has made the veteran worker&#8217;s departure particularly challenging. &#8220;Because your company failed to convert your intellectual insights into SOPs, process docs, or internal databases, that knowledge remains yours. Quietly honor that. It's now part of the value you bring to your next role,&#8221; another user advised.
<h2 class="wp-block-heading">Coast, Don&#8217;t Overextend</h2>
Other users took a more direct approach, suggesting the worker avoid overextending. &#8220;Don&#8217;t finish any current assignments,&#8221; one person wrote, while another added, &#8220;Teach them how to pass the test, nothing more, nothing less.&#8221;
Others also suggested a strategic approach to the training, encouraging the worker to share only the bare minimum. &#8220;Train them on what's already developed. If you can assign any training videos or reading, do it,&#8221; one person recommended.&nbsp;
Trending: The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a>
Another echoed this, adding, &#8220;Quiet train them! Show them where everything is that has been documented, but don't explain what you have figured out on your own over the years.&#8221;
Others even proposed malicious compliance. &#8220;Do as bad a job of training as you possibly can. You can train them on stuff that's not even relevant to day-to-day if you want,&#8221; one user suggested.
Many commenters also warned against walking away entirely, as it could impact unemployment benefits. &#8220;You can still get unemployment if they fire you,&#8221; one commenter noted, adding that coasting through the final days without overextending is often the best approach.
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
<h2 class="wp-block-heading">Consider Future Consulting</h2>
Others proposed an even more calculated exit strategy, encouraging the worker to consider a future <a href="https://www.benzinga.com/news/24/09/40723974/steve-jobs-once-said-management-consultants-bring-very-little-value-compared-to-business-owners-you">consulting role</a>. &#8220;When they call in three weeks begging for more in-depth training, the consulting fee is $500/hour with a 20-hour minimum,&#8221; one user suggested, reflecting a broader sentiment that the worker's unique experience has significant value.
One user highlighted the importance of staying professional while subtly setting boundaries. &#8220;If you feel the need to create anything, type up a daily tasks list at the end of the first week. Just bullet points. Keep it basic, no explanations.&#8221;
The original poster has yet to share how he plans to handle the situation, but the outpouring of support from the online community shows there&#8217;s a shared frustration among workers asked to give more on their way out the door.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market">Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

An IT Veteran Says He's Being Laid Off But Asked To Train His Replacements. He Refuses To Be 'Used Then Tossed Aside Like Garbage'

SPOT Moves Up Almost 24 Points
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12202826/Screenshot-2025-05-12-at-4.21.20%E2%80%AFPM-1024x1015.png" alt="" class="wp-image-12839" /></figure>
Spotify Technology, S.A.. (SPOT) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:10 AM on May 12th, a significant trading signal occurred for Spotify Technology S.A. (SPOT) as it demonstrated a Power Inflow at a price of $608.51. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Spotify&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Spotify&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for SPOT, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $608.51. The returns on the High price ($632.21) and Close price ($620.81) after the Power Inflow are respectively 3.9% and 2.0%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of future results

Equities

WIIM

Technicals

Opinion

Signals

Trading Ideas

Why Spotify Stock Rose As Much As 3.9% After 10:10 AM On May 12

Verb Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) reported quarterly losses of $(2.51) per share which beat the analyst consensus estimate of $(2.99) by 16.05 percent. This is a 250900 percent decrease over losses of $(0.00) per share from the same period last year. The company reported quarterly sales of $1.30 million which beat the analyst consensus estimate of $800.00 thousand by 63.13 percent. This is a 18.54K percent increase over sales of $7.00 thousand the same period last year.

Earnings Beats

VERB

Verb Tech Q1 EPS $(2.51) Beats $(2.99) Estimate, Sales $1.30M Beat $800.00K Estimate

Baird analyst Catherine Schulte maintains Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) with a Neutral and lowers the price target from $3 to $2.

MRVI

Baird Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $2

Macro Economic Events

Econ #s

Economics

US Core CPI (YoY) (Apr) +2.8% vs +2.8% Est.; Prior +2.8%

Macro Notification

USA CPI (MoM) For April 0.2% Vs 0.3% Est.; -0.1% Prior

US CPI (YoY) (Apr) +2.3% vs + 2.4% Est.; Prior +2.4%

Core CPI MoM For For April 0.2% Vs 0.3% Expected; 0.1% Prior

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and lowers the price target from $54 to $42.

KPTI

Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $42

Needham analyst Ryan MacDonald reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and maintains $15 price target.

Reiteration

Needham Reiterates Buy on Evolent Health, Maintains $15 Price Target

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Outperform and lowers the price target from $8 to $4.

EDIT

Baird Maintains Outperform on Editas Medicine, Lowers Price Target to $4

Honda Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) reported quarterly earnings of $0.18 per share. This is a 81.82 percent decrease over earnings of $0.99 per share from the same period last year. The company reported $35.15 billion in sales this quarter. This is a 3.94 percent decrease over sales of $36.59 billion the same period last year.

Honda Motor Co Q4 EPS $0.18 Down From $0.99 YoY, Sales $35.15B Down From $36.59B YoY

Baird analyst Joel Beatty maintains Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) with a Outperform and lowers the price target from $58 to $50.

DNTH

Baird Maintains Outperform on Dianthus Therapeutics, Lowers Price Target to $50

Telsey Advisory Group analyst Cristina Fernandez maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Outperform and maintains $65 price target.

Comments

DeepMarkit

DeepMarkit (MKTDF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO